Diagnosis and Management of Mild Cognitive Impairment

Diagnostic Approach

The American Academy of Neurology recommends conducting formal neuropsychological testing using validated instruments, such as Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), or Modified MMSE (3MS), to objectify cognitive deficit 1, 2.
Evaluate episodic memory, as it is the most characteristic domain for patients who later progress to dementia due to Alzheimer's disease 1, 2.
Exclude disturbances in other cognitive domains: executive functions, speech, spatial skills, and attention 2.

Determine the degree of functional impairment using validated scales, such as Functional Activities Questionnaire (FAQ), Disability Assessment in Dementia (DAD), or Functional Assessment Staging Scale (FAST) 3.
Key criterion for MCI: mild disturbances in complex daily tasks (instrumental activities of daily living - IADL) but preserved basic activities of daily living (ADL), and the patient does not meet the criteria for dementia 1, 2.

Conduct laboratory tests: thyroid function, vitamin B12, homocysteine, complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate, and C-reactive protein 6.
Evaluate vascular risk factors: history of stroke or transient ischemic attack, hypertension, hyperlipidemia, and diabetes 4, 6.
Exclude other causes: depression, recent delirium, head trauma, untreated sleep apnea, and use of anticholinergic or sedative medications 4, 6, 3.

Perform structural neuroimaging of the brain using MRI (or CT if MRI is contraindicated) to exclude vascular lesions, tumors, hydrocephalus, and hemorrhages 6.
MRI may reveal atrophy of the medial temporal lobe, a marker of neurodegeneration in Alzheimer's disease 7.

Consider using Alzheimer's disease biomarkers (after consulting the patient) as an addition to clinical evaluation for predicting functional decline or conversion to dementia due to Alzheimer's disease 7.
Biomarkers are particularly useful in clinically uncertain cases, atypical presentations, rapid progression, or complex behavioral symptoms 6, 3.

Conduct serial assessments of cognitive function using the same instrument, preferably at intervals of at least 6 months, to reduce the practice effect 6.
Obtain objective evidence of progressive cognitive decline over time, which is essential for establishing the accuracy of the diagnosis and evaluating any potential response to treatment 1, 2.

Monitor and manage vascular risk factors (hypertension, diabetes), as they impact the progression of dementia 3.
Memantine may be considered for the treatment of vascular cognitive impairment in individual patients 4.
Ensure an assessment of caregiver needs in education, support, and respite services 3.
Consider referral to specialists (neurologist, geriatrician, geriatric psychiatrist, neuropsychologist) in cases of atypical presentations, rapid progression, or complex behavioral symptoms 6, 3.